- Home
- TENX vs CDT Comparison
TENX vs CDT Comparison
Compare TENX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- CDT
- Stock Information
- Founded
- TENX 1967
- CDT 2019
- Country
- TENX United States
- CDT United States
- Employees
- TENX N/A
- CDT N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- CDT Health Care
- Exchange
- TENX Nasdaq
- CDT Nasdaq
- Market Cap
- TENX 11.4M
- CDT 10.9M
- IPO Year
- TENX N/A
- CDT N/A
- Fundamental
- Price
- TENX $4.94
- CDT $0.09
- Analyst Decision
- TENX Strong Buy
- CDT
- Analyst Count
- TENX 4
- CDT 0
- Target Price
- TENX $20.67
- CDT N/A
- AVG Volume (30 Days)
- TENX 96.4K
- CDT 14.6M
- Earning Date
- TENX 11-13-2024
- CDT 11-26-2024
- Dividend Yield
- TENX N/A
- CDT N/A
- EPS Growth
- TENX N/A
- CDT N/A
- EPS
- TENX N/A
- CDT N/A
- Revenue
- TENX N/A
- CDT N/A
- Revenue This Year
- TENX N/A
- CDT N/A
- Revenue Next Year
- TENX N/A
- CDT N/A
- P/E Ratio
- TENX N/A
- CDT N/A
- Revenue Growth
- TENX N/A
- CDT N/A
- 52 Week Low
- TENX $2.77
- CDT $0.08
- 52 Week High
- TENX $41.92
- CDT $7.83
- Technical
- Relative Strength Index (RSI)
- TENX 64.74
- CDT 39.66
- Support Level
- TENX $4.50
- CDT $0.09
- Resistance Level
- TENX $5.09
- CDT $0.11
- Average True Range (ATR)
- TENX 0.27
- CDT 0.01
- MACD
- TENX 0.01
- CDT 0.00
- Stochastic Oscillator
- TENX 81.01
- CDT 21.54
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.